[Session 7-1]Mitigating Idiosyncratic Toxicity Risks with the N1-substituted-6-arylthiouracils Class of Myeloperoxidase Inactivators: Identification of a Clinical Candidate to Treat Cardiovascular Diseases
○Amit Kalgutkar (Pharmacokinetics, Dynamics and Metabolism Department, Pfizer Inc.)
Password required to view
Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.
You can find the password on the inside front cover of the program book.
Password is required to view the abstract. Please enter a password to authenticate.
You can find the password on the inside front cover of the program book.